QNTM — Quantum Biopharma Ltd.
Is QNTM overbought or oversold? Here is the current MarketMoodz read.
Quantum Biopharma Ltd. (QNTM) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $1.44. The rating moved from Oversold to Strong Oversold on November 17, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$1.44
- Last changeMoved from Oversold to Strong Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Quantum Biopharma Ltd. is a small‑cap biopharma with limited public financial transparency and typical sector risks: dependency on clinical/regulatory readouts, potential financing/dilution, and low liquidity. Current market preference for large‑cap pharma and defensive healthcare reduces near‑term demand for speculative names unless a clear catalyst (positive trial result, partnership, or non‑dilutive financing) emerges. The outlook is highly binary and driven by corporate‑level newsflow; absent fresh positive developments, price volatility and downside from financing risk are the primary concerns.
Key factors
- Limited publicly available financial disclosures (no EDGAR comparison provided) creates low visibility into cash runway and revenue profile
- Small‑cap biopharma profile implies dependence on near‑term clinical/regulatory catalysts or licensing deals to drive meaningful share appreciation
- Sector flows currently favor large‑cap pharma and defensive healthcare, which may limit investor appetite for early‑stage or smaller names
- Industry readthroughs (regulatory receptivity to outpatient/home treatments and device approvals) could benefit companies with relevant assets or partnerships
- Convertible‑debt / financing pressure in the sector raises the prospect of dilution for mid/small‑cap biopharma issuers lacking robust credit access
Risks
- Cash runway uncertainty and need to raise capital leading to equity dilution or expensive financing
- Clinical or regulatory setbacks for any key programs that would materially reduce valuation
- Low liquidity and high share‑price volatility typical of small‑cap biopharma names
- Competitive risk from larger pharma companies or approved alternatives (M&A and large‑cap R&D advantage)
- Macroeconomic or market rotations away from speculative healthcare risk assets, reducing retail and institutional demand
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for QNTM — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.